8-K filed Jun 15, 2026 at 08:15 ET
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve statistical significance on the primary endpoint, leading to discontinuation of its lead pipeline asset. The company is implementing a 35% workforce reduction to generate ~$10M in annualized savings, incurring ~$2M in restructuring costs, and amended its loan agreement to extend the interest-only period and adjust liquidity covenants. Cash runway is extended into Q3 2027, but the loss of the most advanced program is a severe setback for this clinical-stage biotech.